Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Study on the Feasibility and Acceptability of Pericoital Levonorgestrel 1.5mg

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04058873
Recruitment Status : Recruiting
First Posted : August 16, 2019
Last Update Posted : November 13, 2019
Population Council
Marie Stopes International
Bill and Melinda Gates Foundation
The Children's Investment Fund Foundation
Information provided by (Responsible Party):
Camber Collective

Brief Summary:
This study intends to build on the previous research and gather data in an actual use study / patient registry of pericoital LNG 1.5mg to understand women's acceptability of the product along with associated side effects, monitoring for their correct and incorrect use. These findings will contribute to the discussion around the feasibility of pericoital LNG as an additional contraceptive by adding to the body of evidence.

Condition or disease Intervention/treatment
Pregnancy Related Drug: Levonorgestrel 1.5mg

Detailed Description:

The study would consist of distributing pericoital LNG 1.5mg tablet across 75 pharmacy sites in Ghana over the course of 12 months. Recruitment will be staggered, and women will be recruited up to 6 months into the study. As such, the data collection period per participant will be at least 6 months per participant.

Consistent with the recent WHO study (Festin et al. " A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using LNG 1.5mg" (2016)), participants will be given instructions on how to correctly use LNG 1.5mg, namely to take one pill 24 hours before or after sexual relations, and no more than 6 times per month. Contraceptive protection requires use only once per 24 hours, regardless of how many times sexual relations are had during those 24 hours.

Participants will include a broad population of women age 18-49, not currently on any long-term modern method, who do not wish to get pregnant in the following 6 months but would not consider it a serious issue if they did become pregnant. They will be asked to use LNG 1.5mg as their exclusive method of contraception for the period of the study, with the exception of condoms.

The drug used for the study is LNG 1.5mg, specifically Marie Stopes International's BK-1 pill, repackaged for the study purposes. The BK-1 pill is currently registered as an emergency contraceptive and sold in Ghana with good quality assurance procedures in place. The BK-1 emergency contraception pill is manufactured for Marie Stopes International by Acme Formulation Pvt., Limited, one of the leading drug manufacturers of India. It is registered as an emergency contraception by the Food and Drugs Authority in Ghana and assigned registration number FDA/SD.183-11710. The package will read "LNG 1.5mg for Pericoital Use - for study purposes only" and be devoid of any other branding (please see Appendix for artwork).

Data collection components with research participants include:

  1. Baseline background information about the research participants will be collected during the screening (e.g., qualifications for inclusion/ exclusion) and enrollment process
  2. Weekly SMS / WhatsApp / phone call surveys with research participants. They will be asked 10 questions about user satisfaction, circumstances of use, and outcomes (e.g., self-reported side effects)
  3. Two follow up face to face surveys per participant to better understand participant perception of LNG 1.5mg, customer satisfaction with product and service, and future contraceptive intentions (at month 2 and month 6)

Data collection components with pharmacies will include:

  1. Baseline data of average packs of FP products sold at the pharmacy, in order to understand the overall increase in FP methods sold over the course of the study
  2. A mystery shopping survey to check the quality of service provision and monitoring of recruitment/quality of information at each of the 75 study sites every 4 to 6 weeks. This will amount to at least 6 visits per site over the 12 months of the study.
  3. Register collected at pharmacy point of sale, with units sold over the course of the 12-month pilot. Note: participants will be able to go to any of the participating pharmacies during the course of the project.
  4. Pharmacists feedback surveys to understand the provision of LNG 1.5mg: a baseline survey before the training and a survey during month 8 of the study

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Study on the Feasibility and Acceptability of Pericoital Levonorgestrel 1.5mg
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : October 1, 2020

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Levonorgestrel 1.5mg
    Levonorgestrel 1.5mg for pericoital use

Primary Outcome Measures :
  1. feasibility of use [ Time Frame: 6 months ]
    Self reported via bi-weekly survey: women are able to access and use product correctly (consistent with instructions from health care provider / pharmacist)

  2. acceptability [ Time Frame: 6 months ]
    Self reported via bi-weekly survey: Understand drivers behind decision-making of using pericoital LNG 1.5mg, conditions of use, and potential impact on increased mCPR and intention to use longer-term methods in the future

Secondary Outcome Measures :
  1. side effects [ Time Frame: 6 months ]
    Self reported via bi-weekly survey: self reported side effects from using product

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female only
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
women from areas surrounding distribution sites (pharmacies)

Inclusion Criteria:

  • between the age of 18-49 years, is willing to use LNG 1.5 mg tablets as her primary contraceptive method, wants to avoid pregnancy for at least the next 6 months after enrollment, is willing to accept an uncertain risk of pregnancy during the study, and understands that the risk of pregnancy on this method would be slightly higher than other methods of contraception

Exclusion Criteria:

  • women using one or more of the following contraceptive methods: daily pill, injectable, implant, sterilization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04058873

Layout table for location contacts
Contact: Jessica Vandermark +33623277739

Layout table for location information
Marie Stopes International Ghana Recruiting
Accra, Ghana
Contact: Henry Bruce    +233 (0) 302 241 517 ext 132   
Sponsors and Collaborators
Camber Collective
Population Council
Marie Stopes International
Bill and Melinda Gates Foundation
The Children's Investment Fund Foundation
Layout table for investigator information
Principal Investigator: Saumya Ramarao Population Council
Principal Investigator: Emmanuel Kuffour Population Council

Publications of Results:
Layout table for additonal information
Responsible Party: Camber Collective Identifier: NCT04058873    
Other Study ID Numbers: 2019LNG1.5mg
First Posted: August 16, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral